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Context: Experimental studies suggest that aldosterone induces hypercalciuria andmight contrib-
ute to hyperparathyroidism.
Objective: We aimed to test for differences in PTH levels and parameters of calcium and vitamin
D metabolism in patients with primary aldosteronism (PA) compared with patients with essential
hypertension (EH) and to evaluate the impact of PA treatment on these laboratory values.
Design, Setting, and Participants: The Graz Endocrine Causes of Hypertension study includes
hypertensive patients referred for screening for endocrine hypertension at a tertiary care center
in Graz, Austria.
Main Outcome Measures: Differences in PTH levels between patients with PA and EH.
Results:Among192patients,we identified10patientswithPAand182withEH.PTH levels (mean
SD inpicogramspermilliliter)were significantlyhigher inPApatients comparedwithEH(67.826.9
vs. 46.5  20.9; P  0.002). After treatment of PA with either adrenal surgery (n  5) or miner-
alocorticoid receptor antagonists (n 5), PTH concentrations decreased to 43.9 14.9 (P 0.023).
Serum25-hydroxyvitaminD concentrationswere similar in both groups. Comparedwith EH, serum
calcium concentrations were significantly lower (2.35 0.10 vs. 2.26 0.10mmol/liter; P 0.013),
and there was a nonsignificant trend toward an increased spot urine calcium to creatinine ratio in
PA [median (interquartile range) 0.19 (0.11–0.31) vs. 0.33 (0.12–0.53); P  0.094].
Conclusions: Our results suggest that PA contributes to secondary hyperparathyroidism. Further
studies are warranted to evaluate whether PTH has implications for PA diagnostics and whether
mineralocorticoid receptor antagonists have a general impact on PTH and calcium metabolism.
(J Clin Endocrinol Metab 97: E75–E79, 2012)
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Primary aldosteronism (PA) is associatedwith an excesscardiovascular morbidity and mortality risk that
cannot be explained by arterial hypertension alone (1).
Hence, aldosterone excess may exert deleterious effects
beyond blood pressure regulation. Apart from various
harmful aldosterone effects on heart and vessels, evidence
exists that aldosterone may also impact on mineral ho-
meostasis by increasing renal and fecal loss of calcium and
magnesium (2–5). This in turnmay stimulate the secretion
ofPTH.ElevatedPTHis, beyond itswell-knowneffects on
bone and calcium metabolism, also considered a cardio-
vascular risk factor (6, 7). In this context, experimental
studies in rats have shown that aldosterone excess is ac-
companied by secondary hyperparathyroidism that is re-
versible by mineralocorticoid receptor (MR) antagonist
therapy (2, 3).Humandata on this topic are sparse, butwe
and others have previously shown significant associations
of PTHand aldosterone levels (5, 7, 8). In addition, results
from some small clinical studies indicate that PA may be
accompanied by hyperparathyroidism, but these studies
were largely limited by inadequate characterization of cal-
cium and vitamin D metabolism (9–11). We therefore
evaluated in hypertensive patients derived from the Graz
Endocrine Causes of Hypertension (GECOH) study
whether PA and its treatment are associated with altera-
tions in PTH levels, parameters of calcium homeostasis,
and vitamin D status (12).
Subjects and Methods
Study population
The GECOH study is a diagnostic accuracy study of the al-
dosterone to active renin ratio (AARR) in screening for PA. The
study protocol of the GECOH study has been published previ-
ously (12). In brief, the GECOH study population consists of
adult patients (age 18 yr), who are routinely referred to our
outpatient clinic for screening for endocrine hypertension.Main
inclusion criterionwas arterial hypertension andmain exclusion
criterion was intake of drugs that significantly interfere with the
renin angiotensin aldosterone system (RAAS) (i.e. spironolac-
tone, canrenoate, eplerenone, amiloride, triamteren, and/or al-
iskiren) 4 wk before study entry. Study participants of this single
center study at the Medical University of Graz (Graz, Austria)
undergo a standardized procedure for PA diagnostics including
two determinations of the AARRand a saline infusion test (SIT).
Based on these examinations, PA is diagnosed in those patients
with at least one AARR of 3.7 ng/dl  U per milliliter or greater
(5.7 ng/dl  ng per liter, equivalent to an aldosterone to renin
activity ratio of30 ng/dl  ng/ml per hour) and an aldosterone
level of 10 ng/dl or greater after the SIT.
Adrenal computed tomography and adrenal venous sampling
was performed in PA patients to differentiate between bilateral
idiopathic hyperaldosteronism (IHA) and unilateral aldoste-
rone-producing adrenal adenoma (APA). In a follow-up visit, PA
patientswere examined at our outpatient clinic after initiation of
medical or surgical treatment of PA. Furthermore, all patients
were evaluated for parameters of calcium metabolism (serum
calcium, vitamin D status, PTH, and urinary calcium) and for
other endocrine forms of arterial hypertension (e.g. pheochro-
mocytoma or Cushing’s disease). In detail, we systematically
measured plasma metanephrines and midnight salivary cortisol
as screening tests and performed routine confirmatory tests in
those patients with significantly elevated levels and clinical
symptoms of either Cushing’s disease or pheochromocytoma.
Blood pressure (BP) was measured by the method of Korotkoff
after 5 min at rest and by using a sphygmomanometer with an
appropriate cuff. Systolic anddiastolicBPweremeasuredat both
arms and the mean values out of both measurements were re-
corded. Height and weight were measured wearing light clothes
and no shoes. Written informed consent was obtained from all
study participants, and the Ethics Committee at the Medical
University of Graz approved the study.
Laboratory methods
Laboratory methods have been previously described in detail
(12). All blood samplingswere performed after an overnight fast
between 0800 and 1100 h and after the patients were seated for
10 min. Patients were on an unrestricted Western diet and were
advised to avoid both smoking and any medication intake in the
morning before blood sampling. Midstream spot urine samples
were also collected at baseline. All parametersweremeasured on
a daily or weekly basis at our laboratory. Plasma aldosterone
concentration was measured by RIA (active aldosterone RIA
DSL-8600;Diagnostic Systems Laboratories, Inc.,Webster, TX)
with an intra- and interassay coefficient of variation (CV) of
3.3–4.5 and 5.–9.8%, respectively. Plasma active renin concen-
trationswere alsodeterminedbyRIA (renin immunoradiometric
assayRIA-4541;DRG InstrumentsGmbH,Marburg,Germany)
with an intra- and interassay CV of 0.6–4.5 and 2.7–14.5%,
respectively. Intact PTH was determined in plasma by electro-
chemiluminescence immunoassay on an Elecsys 2010 (Roche
Diagnostics, Mannheim, Germany), with a normal range of
15–65 pg/ml and an interassay CV of 5.7–6.3%. Measurement
of 25-hydroxyvitaminD [25(OH)D]was performedbymeans of
a chemiluminescenceassay (IDS-iSYS25-hydroxyvitaminD; Im-
munodiagnostic Systems Ltd., Boldon, UK) on an IDS-iSYSmul-
tidiscipline automated analyzer. The within-day CV were 5.5–
12.1%, and the interday CV were 8.9–16.9%, respectively.
Serum calcium and urinary calcium were measured by using
the Roche/Hitachi cobas c system analyzer (Roche Diagnos-
tics). All other parameters were determined by routine labo-
ratory procedures.
Statistical analyses
Depending on their distribution, continuous data are either
presented as means  SD (normally distributed variables) or as
medians with interquartile ranges (skewed variables). Variables
following a nonnormal distribution were logarithmically trans-
formed before use in parametric analyses. Categorical variables
are presented as percentages. Comparisons between patients
with essential hypertension (EH) and patients with PAwere per-
formed with an unpaired Student’s t test and an analysis of co-
variance for continuous parameters and with Fisher’s exact test
for categorical variables. Paired Student’s t tests were used to
evaluate differences in continuous parameters in PA patients be-
fore and after treatment, and we calculated Pearson correlation
E76 Pilz et al. Hyperparathyroidism in Primary Aldosteronism J Clin Endocrinol Metab, January 2012, 97(1):E75–E79
coefficients to test for associations between continuous vari-
ables. A P 0.05 was considered statistically significant, and
SPSS version16.0 (SPSS Inc.,Chicago, IL)was used for statistical
analyses.
Results
Between February 2009 and April 2011, we included 195
patients into the GECOH study. Three patients were sub-
sequently excluded from the present analysis because they
refused to undergo the SITdespite elevatedAARR, andwe
could thus not confirm or exclude PA. Among the remain-
ing 192 patients, we diagnosed 10 patients with PA, 182
patients with EH, and no patient with other cause of en-
docrine hypertension (pheochromocytoma andCushings
disease excluded). Furthermore, significant renal artery
stenosiswas excluded inall PApatients by routine imaging
methods. Baseline characteristics for patientswithEHand
PA at the baseline study visit as well as for PA patients at
the follow-up visit are shown in Table 1. As expected,
there were marked differences in the parameters of the
RAAS between patients with PA and EH. Compared with
EH, PTH levels were significantly increased, and serum
calcium as well as albumin corrected calcium was signif-
icantly decreased in patients with PA (Table 1). There was
a nonsignificant trend toward an increased spot urine cal-
cium to creatinine ratio in patientswith PA, but therewere
no significant group differences in 25(OH)D levels. At
baseline, only one patient with PA and five patients with
EHwere on calcium and vitamin D supplementation, and
at follow-up, only one patientwith PA received additional
vitamin D supplementation, whereas no PA patient was
treated with any other drugs that could significantly in-
terfere with calcium or bone metabolism. The use of di-
uretics was not significantly different in patients with PA
and EH (50 vs. 39%; P  0.516), and the spot urine cal-
cium to creatinine ratio was similar in patients with and
without the use of diuretics [0.20 (0.12–0.32) vs. 0.17
(0.10–0.32), P  0.861].
PTH levels were significantly increased in PA and were
reduced to the level of EH after specific treatment (Table
1 and Fig. 1). Considering that body mass index (BMI) is
a known predictor of PTH levels, we adjusted for BMI but
PTH levels remained significantly elevated in PA com-
pared with EH (P  0.019). Pearson correlation coeffi-
cients of aldosterone and PTH in all 10 PA patients were
0.632 (P  0.050) before treatment and 0.368 (P 
0.330) after treatment. Furthermore, there was no signif-
icant correlation between the changes in PTH and in
25(OH)Dbefore and after PA treatment (r0.314;P
0.256). Five PA patients were diagnosed as IHA and five
patients as APA. In patients with IHA, who were all sub-
sequently treated with MR antagonists (two on 25 mg
eplerenone daily and three on 25–50 mg spironolactone
TABLE 1. Clinical and laboratory characteristics of the GECOH study population
Variable
Essential
hypertension (EH)
PA before
treatment (PABT)
PA after
treatment (PAAT)
EH vs.
PABT
P valuea
PABT vs.
PAAT
P valueb
n 182 10 10
Age (yr) 50.2  15.7 50.1  11.0 51.2  11.5 0.988 0.002
Females (%) 59.3 60.0 1.000
Females, postmenopausal (%) 53.7 50.0 0.859
Aldosterone (ng/dl) 16.0 (12.3–23.4) 33.6 (24.4–67.8) 31.0 (9.1–53.4) 0.001 0.267
PRC (U/ml) 11.9 (5.9–28.2) 3.1 (2.8–4.4) 16.1 (10.2–24.1) 0.001 0.001
AARR (ng/dl  U per milliliter) 1.5 (0.6–2.8) 11.1 (5.1–21.8) 1.9 (0.7–3.4) 0.001 0.005
BMI (kg/m2) 28.5  6.0 31.0  7.1 NA 0.270 NA
Systolic blood pressure (mm Hg) 154  23 179  22 149  23 0.006 0.018
Diastolic blood pressure (mm Hg) 94  13 108  12 96  13 0.005 0.050
Serum potassium (mmol/liter) 3.9  0.4 3.2  0.3 4.2  0.4 0.001 0.001
Serum sodium (mmol/liter) 141 (140–143) 144 (142–146) 140 (138–142) 0.001 0.001
Creatinine (mg/dl) 0.90 (0.79–1.02) 0.88 (0.74–1.11) 1.16 (0.93–1.44) 0.676 0.005
PTH (pg/ml) 46.5  20.9 67.8  26.9 43.9  14.9 0.002 0.023
25(OH)D (ng/ml) 30.5  15.0 33.0  23.7 41.2  22.3 0.748 0.185
Serum calcium (mmol/liter) 2.35  0.10 2.26  0.10 2.35  0.12 0.013 0.100
Albumin–corrected calcium
(mmol/liter)
2.23  0.10 2.14  0.10 NA 0.006 NA
Serum phosphate (mgl/dl) 2.92  0.55 2.52  0.68 3.1  0.5 0.029 0.095
Urinary calcium to creatinine ratioc 0.19 (0.11–0.31) 0.33 (0.12–0.53) NA 0.094 NA
Continuous data are presented as means  SD or as medians with interquartile ranges. PRC, Plasma renin concentration; NA, not available.
a P value for unpaired Student’s t test for continuous variables and for Fishers exact test for categorical variables.
b P value for paired Student’s t test.
c Data for only 167 patients with EH and nine patients with PA.
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daily), PTH levels (in picogramspermilliliter)were 58.9
15.5 before and 47.1  18.6 after drug treatment (P 
0.132). In patients with APA, who were all treated by
removal of a histopathologically confirmed adrenal ade-
noma, PTH levels were 76.7  34.4 before and 40.6 
11.1 after surgery (P 0.077). Follow-up visits were per-
formed after a median of 3.7 months (range 0.3–19.5
months) after the start of PA treatment. In detail, fol-
low-up visits were performed after a median of 1.0month
(range 0.4–15.9 months) after adrenal surgery in patients
with APA and after a median of 6.3 months (range 0.3–
19.5 months) after the start of MR blocker therapy in
patients with IHA. BP in treated PA patients was either
improved or was similar compared with baseline values
but with a reduced number or dose of antihypertensive
drugs. In addition, we performed a second follow-up ex-
amination among eight PA patients after amedian of 22.2
months (range 3.4–27.6 months) after the start of PA
treatment. In that follow-up visit, PTH levels (in pico-
grams per milliliter) remained significantly reduced com-
pared with baseline (41.4  11.4 vs. 59.4  21.1, P 
0.037).
Discussion
We have shown that compared with EH, patients with PA
have higher PTH levels that are significantly reduced after
targeted treatment of PA. These differences in PTH levels
were accompanied by reduced baseline serum calcium lev-
els in PA patients, and we observed a nonsignificant trend
for increased baseline urinary calcium excretion in PA.
Previous studies in rats demonstrated increased urinary
and fecal calcium excretion and bone loss in the setting of
experimental aldosteronism that could be attenuated by
spironolactone treatment (3–5, 13, 14). Our results sup-
port the concept that PA may lead to secondary hyper-
parathyroidism. We confirm the finding of a previous
study that showed similar data in PA patients but did not
report on vitamin D status (10). In general, the results of
the GECOH study support the concept that aldosterone
excess in the setting of PA may decrease serum calcium
levels, likewise by increased urinary calcium loss, andmay
thereby contribute to secondary hyperparathyroidism.
Importantly, PA treatment in the GECOH study had a
remarkable suppressive effect on PTH levels. In fact, after
targeted treatment of PA, PTH levels in patients on MR
antagonists or after adrenal surgery were similar com-
pared with patients with EH. Changes in PTH levels ap-
peared to be more pronounced in patients with APA
treated by surgery compared with patients with IHA
treated by MR antagonists, but we should be cautious
with interpreting results of very small subgroups.Whether
PTH elevations may partially underlie the excess cardio-
vascular risk in PA warrants further studies.
Apart from PA, the proposed link of aldosterone and
PTH may be also of clinical relevance when considering
the widespread use of spironolactone for the treatment of
heart failure patients, who are also prone to secondary
hyperparathyroidism (15). Interestingly, it has been ob-
served that the use of spironolactone is associated with
reduced fracture risk in heart failure patients, a result that
may hypothetically be driven by bone effects of PTH (16).
Hence, an important research question for future studies
is the impact of MR antagonists on PTH and calcium
metabolism in patients without PA. Apart from this, it is
interesting to note that there are reports on hypercalcemia
and suppressed PTH in adrenal insufficiency that can be
corrected after hormonal substitutive therapy (17). Al-
though our study aimed to test whether PA is associated
with hyperparathyroidism, we have to acknowledge that
there is also evidence for a potential reverse causation, i.e.
that PTH itself may stimulate the RAAS (8, 18–21). Fu-
ture studies should therefore evaluate the complex inter-
play of PTH and RAAS and should clarify whether PTH
measurements might be useful for diagnostics of PA.
Our results are limited by the relatively small sample
size of patients with PA, the observational nature of our
study, and some limitations related to the characterization
of calcium metabolism (e.g.missing data on 24 h urinary
calcium excretion, follow-up urinary samples, or ionized
serum calcium). Furthermore, our work is only a second-
ary outcomes analysis of the GECOH study and our data
were derived from aCaucasian cohort of hypertensive pa-
tients. Our findings may therefore not be generalizable to
other study populations.
In conclusion, our results show that PA patients are
prone to secondary hyperparathyroidism that can be suc-
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FIG. 1. PTH serum concentrations before and after specific treatment
of PA with either adrenal surgery (gray crosses) or MR antagonists
(black circles).
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cessfully treated withMR antagonists or adrenal surgery.
Further studies are warranted to evaluate whether PTH
has implications for diagnostic procedures for PA and
whether MR antagonists have, beyond PA, a general im-
pact on PTH and calcium metabolism.
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